Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Simon Shuster, Senior Correspondent at TIME, discusses his recent article, how the friendship between Musk and Trump may affect US spending, “DOGE” and more.
Christa Pitts, Co-Founder & Co-CEO of The Lumistella Company shares the origins of Elf on the Shelf Plus Extraordinary Noorah's Macy's Day Parade debut!
Hayley Berg, Lead Economist at Hopper breaks down her best tips for navigating holiday travel and how to score the hottest deals on Dec. 3 - Travel Deal Tuesday
MarketWatch's Hannah Erin Lang joins Cheddar to discuss how economists are viewing Trump's immigration policy and how it will affect the job market in America.
Zack Malet, Senior Director of Business Development & Innovation, joins Cheddar to discuss ESPN experiences and how they are changing the sports travel game.
Smashburger CEO Denise Nelsen discusses how her time building the Starbucks brand gave her the tools to lead a Smashburger brand refresh, value wars, and more.
